Masatoshi Kudo, MD, PhD, Kindai University

Articles by Masatoshi Kudo, MD, PhD, Kindai University

Future Directions of HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Using AFP as a Biomarker in HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.

Sequencing With Anti-PD-1 Antibodies in HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Amit Singal, MD; Masatoshi Kudo, MD, PhD; and Stephen L. Chan, MD, share their personal approaches to sequencing with an anti-PD-1 antibody after first-line atezolizumab-bevacizumab in HCC (hepatocellular carcinoma).

CELESTIAL and RESORCE Trials in HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

April 7th 2021

Amit Singal, MD, comments on the use of cabozantinib in patients with Child-Pugh A and Child-Pugh B disease as well as regorafenib in advanced stage HCC (hepatocellular carcinoma).

Role of VEGF TKIs for Second-Line Therapy in HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

April 7th 2021

Considerations for selecting a VEGF TKI (tyrosine kinase inhibitor) in the second-line setting for the management of HCC (hepatocellular carcinoma).

Approaching Second-Line Therapy in HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 31st 2021

Amit Singal, MD, shares his thoughts on approaching second-line therapy for HCC (hepatocellular carcinoma) after first-line atezolizumab-bevacizumab as well as options for patients with Child-Pugh B disease who are ineligible for frontline atezolizumab-bevacizumab.

KEYNOTE-240 and HIMALAYA Trials in Advanced HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 31st 2021

A review of currently available ongoing data for unresectable HCC (hepatocellular carcinoma), including data from the HIMALAYA trial.

Frontline Trials for Unresectable HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 25th 2021

Amit Singal, MD, MS, and Stephen L. Chan, MD, review the IMbrave150, LEAP-002, and CheckMate 9DW trials for unresectable hepatocellular carcinoma.

TACE-3 and CheckMate 74W Trials for BCLC stage B or stage C HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 25th 2021

Stephen L. Chan, MD, reviews data from key trials of emerging combinations of TACE (transarterial chemoembolization), plus systemic therapies for BCLC (Barcelona Clinic Liver Cancer) stage B or C hepatocellular carcinoma.

Emerging Combinations of TACE for BCLC Stage B/C HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 17th 2021

Masatoshi Kudo, MD, PhD, reviews data from the LEAP-012 and TACTICS trials for intermediate stage hepatocellular carcinoma.

Role of TACE in BCLC Stage B HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 17th 2021

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, comment on the role of TACE (transarterial chemoembolization) in early line settings for the management of BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and whether systemic therapy has the potential to replace TACE.

REFLECT Trial in BCLC Stage B HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 10th 2021

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, review the REFLECT trial and discuss the use of lenvatinib in patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma.

Using Systemic Therapy in BCLC Stage B HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 10th 2021

Assessing outcomes associated with systemic therapy, such as lenvatinib and sorafenib, for patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma based on data from the IMbrave150 and GIDEON trials.

Practical Considerations of TACE: Unresectable BCLC Stage B HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 3rd 2021

Practical considerations for TACE (transarterial chemoembolization) in unresectable BCLC stage B HCC, including assessing radiologic response and determining when to initiate systemic therapy.

Patient Assessment for TACE in Unresectable BCLC Stage B HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

March 3rd 2021

Examining individual patient assessment for using TACE (transarterial chemoembolization) in unresectable BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and the health care team involved.

First-line Locoregional Therapies in Advanced HCC

ByAmit Singal, MD, UT Southwestern Medical Center,Masatoshi Kudo, MD, PhD, Kindai University,Stephan L. Chan, MD, The Chinese University of Hong Kong

February 24th 2021

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, discuss the benefit/risk ratio of first-line locoregional therapies in advanced hepatocellular carcinoma.